Guru Subramanian Guru Murthy

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms

Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis

Association of <scp>ABO</scp> mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia

Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

Outcomes of <scp><i>TP53</i></scp>‐mutated <scp>AML</scp> with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study